A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs VAY 736 (Primary)
- Indications Autoimmune hepatitis
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors Novartis Pharmaceuticals
- 14 Nov 2017 Planned End Date changed from 31 Dec 2020 to 30 Dec 2020.
- 14 Nov 2017 Planned primary completion date changed from 31 Dec 2020 to 30 Dec 2020.
- 17 Jul 2017 New trial record